Displaying 2 (all) recruiting clinical trials.
-
PSMAfore: A phase III Open-label Multi-Center Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Na ve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617, given for 6 weeks at a dose of 7.4 GBq improves the radiographic progression ...Phase
Interventional
-
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer
The purpose of the study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing ...Phase
Interventional
